source
- Voyager Therapeutics CEO Al Sandrock to resign next year, remains on board; Insmed appoints Paul Hudson as directorVoyager Therapeutics announced that its chief executive, Al Sandrock, will step down in the first quarter of next year. Sandrock will continue to serve on Voyager's board after his resignation, pr…
- Family reflects on extra months gained from new pancreatic cancer drug daraxonrasibBobby Senaha was among the first patients to receive daraxonrasib, a new medicine aimed at extending survival for people with pancreatic cancer. The drug is described as life extending, offering p…